X5050|cas:2404756-81-4|西域试剂

X5050,98.00%

产品编号：Bellancom-136833| CAS NO：2404756-81-4| 分子式：C₁₇H₁₅N₃O₃| 分子量：309.32

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-136833	￥3000.00	杭州北京（现货）
Bellancom-136833	￥4800.00	杭州北京（现货）
Bellancom-136833	￥9500.00	杭州北京（现货）
Bellancom-136833	￥14500.00	杭州北京（现货）
Bellancom-136833	￥22500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

X5050

产品介绍

X5050 是 REST 的一个抑制剂，其 EC₅₀ 值为 2.1 μM。

生物活性

X5050 is a REST inhibitor, with an EC₅₀ of 2.1 μM.

体外研究

X5050 (100 µM, 1 day) induces a dosedependent decrease in the REST isoform in protein level.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	NSCs.
Concentration:	100 µM.
Incubation Time:	One day.
Result:	Induced a dosedependent decrease in the 122 kDa longer REST isoform.

体内研究
(In Vivo)

X5050 (2 x 2µl of 20 mM) is active in HD pathological context.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	12-week-old male C57Bl6 mice.2
Dosage:	2 x 2µl of 20 mM in 10% DMSO in water.
Administration:	Intraventricular injection.
Result:	Increased BDNF expression. A decrease in Darpp32 and Snap25 expression was found by QRT-PCR in the lesioned striatum as compared with the contralateral striatum. Significantly increased the levels of Bdnf II splice variant (exon II containing variant) while Bdnf IV levels were not significantly changed.

体内研究

X5050 (2 x 2µl of 20 mM) is active in HD pathological context.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	12-week-old male C57Bl6 mice.2
Dosage:	2 x 2µl of 20 mM in 10% DMSO in water.
Administration:	Intraventricular injection.
Result:	Increased BDNF expression. A decrease in Darpp32 and Snap25 expression was found by QRT-PCR in the lesioned striatum as compared with the contralateral striatum. Significantly increased the levels of Bdnf II splice variant (exon II containing variant) while Bdnf IV levels were not significantly changed.

体内研究

X5050 (2 x 2µl of 20 mM) is active in HD pathological context.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	12-week-old male C57Bl6 mice.2
Dosage:	2 x 2µl of 20 mM in 10% DMSO in water.
Administration:	Intraventricular injection.
Result:	Increased BDNF expression. A decrease in Darpp32 and Snap25 expression was found by QRT-PCR in the lesioned striatum as compared with the contralateral striatum. Significantly increased the levels of Bdnf II splice variant (exon II containing variant) while Bdnf IV levels were not significantly changed.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (323.29 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.2329 mL	16.1645 mL	32.3290 mL
5 mM	0.6466 mL	3.2329 mL	6.4658 mL
10 mM	0.3233 mL	1.6164 mL	3.2329 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (8.08 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.08 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液